Sacituzumab govitecan plus platinum-based chemotherapy in breast, bladder, and lung carcinomas.

A research paper published in Oncotarget's Volume 15 on February 22, 2024, titled "Sacituzumab govitecan plus platinum-based chemotherapy mediates significant antitumor effects in triple-negative breast, urinary bladder, and small-cell lung carcinomas," explores the potential of combining sacituzumab govitecan (SG) with platinum-based chemotherapeutics in treating triple-negative breast cancer (TNBC), urinary bladder carcinoma (UBC), and small-cell lung carcinoma (SCLC). The study found that combining SG with carboplatin or cisplatin produced additive growth-inhibitory effects in vitro and significant antitumor effects in mice bearing TNBC, UBC, and SCLC tumors. The researchers suggest that further clinical investigation is warranted to explore the benefits of this combination therapy. [Extracted from the article]